{"entity":{"id":"joaquim-bellmunt","kind":"person","name":"Joaquim Bellmunt","aka":[],"tldr":"Led KEYNOTE-045, the first trial to show immunotherapy beats chemotherapy in advanced bladder cancer.","summary":"Joaquim Bellmunt was principal investigator of KEYNOTE-045, which showed pembrolizumab improves survival over second-line chemotherapy in platinum-refractory urothelial cancer, the first randomised survival benefit for immunotherapy in the disease. He developed the Bellmunt prognostic score and led the vinflunine and TCGA bladder subtype work. He directs the bladder cancer centre at Dana-Farber.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bellmunt%20J%5BAuthor%5D%20urothelial%20pembrolizumab"}],"tags":["urothelial","immunotherapy"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Bladder Cancer Center, Dana-Farber Cancer Institute; Associate Professor, Harvard Medical School","institutionId":"dana-farber","specialisms":["Urothelial cancer","Immunotherapy","Chemotherapy","Molecular subtypes"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bellmunt%20J%5BAuthor%5D%20urothelial%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma (KEYNOTE-045)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1613683"},{"title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","journal":"Cell","year":2017,"doi":"10.1016/j.cell.2017.09.007"}]},"route":"/people/joaquim-bellmunt/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}]}}